Juliette Hukin

Juliette Hukin

Auto-generated profile, based on publicly available information

Juliette Hukin

Department of pediatrics, Division of Hematology-Oncology, B.C. Children’s Hospital, University of British Columbia

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PBPawel Buczkowicz
Pawel Buczkowicz
CHChristine Hoeman
Christine Hoeman
PRPatricia Rakopoulos
Patricia Rakopoulos
SPSanja Pajovic
Sanja Pajovic
LLLouis Letourneau
Louis Letourneau
CHCynthia Hawkins
Cynthia Hawkins
Cynthia Hawkins, Oren Becher and colleagues report the identification of recurrent mutations in ACVR1 in 20% of diffuse intrinsic pontine gliomas. Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.

1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
JTJonathon Torchia
Jonathon Torchia
BGBrian Golbourn
Brian Golbourn
SFShengrui Feng
Shengrui Feng
KHKing Ching Ho
King Ching Ho
PSPatrick Sin-Chan
Patrick Sin-Chan
AHAnnie Huang
Annie Huang

27 April 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LDLaura K. Donovan
Laura K. Donovan
ADAlberto Delaidelli
Alberto Delaidelli
SJSujith K. Joseph
Sujith K. Joseph
KBKevin Bielamowicz
Kevin Bielamowicz
KFKristen Fousek
Kristen Fousek
MTMichael D. Taylor
Michael D. Taylor

10 October 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAlvaro Lassaletta
Alvaro Lassaletta
KSKatrin Scheinemann
Katrin Scheinemann
SZShayna M. Zelcer
Shayna M. Zelcer
JHJuliette Hukin
Juliette Hukin
BWBeverley A. Wilson
Beverley A. Wilson
EBEric Bouffet
Eric Bouffet
Purpose: Vinblastine monotherapy has shown promising activity and a low-toxicity profile in patients with pediatric low-grade glioma (PLGG) who experienced treatment failure after initial treatment with chemotherapy and/or radiation. The aim of this study was to assess the activity of vinblastine in therapy-naïve children. Patients and Methods: Patients < 18 years old with unresectable and/or progressive therapy-naïve PLGG were eligible. Vinblastine was administered once per week at a dose of 6 mg/m2 intravenously over a period of 70 weeks. Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation/fusion status were also determined and correlated with outcome. Results: Fifty-four patients were enrolled onto the study, with a median age of 8 years (range, 0.7 to 17.2 years). Most patients had chiasmatic/hypothalamic tumors (55.5%), and 13 patients (24.1%) had NF1. The most common histology was pilocytic astrocytoma (46.3%). Seventeen patients were diagnosed using radiologic criteria alone. Best response to chemotherapy was centrally reviewed with a response rate (complete, partial, or minor response) of 25.9%. Disease stabilization (complete, partial, or minor response or stable disease) was achieved in 47 patients (87.0%). Visual improvement was observed in 20% of patients with optic pathway glioma. Five-year overall survival and progression-free survival (PFS) rates were 94.4% (95% CI, 88.5% to 100%) and 53.2% (95% CI, 41.3% to 68.5%), respectively, for the entire cohort. Patients with NF1 had a significantly better PFS (85.1%; 95% CI, 68.0% to 100%) when compared with patients without NF1 (42.0%; 95% CI, 29.1% to 60.7%; P = .012). Age< 3 years or > 10 years was not associated with poor outcome. Treatment was well tolerated, and quality of life was not affected during treatment. In this trial, there was no correlation between BRAF alterations and outcome. Conclusion: Vinblastine administered once per week is well tolerated in children with treatment naïve PLGG. Overall survival and PFS are comparable to current therapies, with a favorable toxicity profile and a maintained quality of life.

20 April 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TMThomas E. Merchant
Thomas E. Merchant
ABAnne E. Bendel
Anne E. Bendel
NSNoah D. Sabin
Noah D. Sabin
PBPeter C. Burger
Peter C. Burger
DSDennis W. Shaw
Dennis W. Shaw
VRVijay Ramaswamy
Vijay Ramaswamy
PURPOSE: The Children’s Oncology Group trial ACNS0121 estimated event-free survival (EFS) and overall survival for children with intracranial ependymoma treated with surgery, radiation therapy, and—selectively—with chemotherapy. Treatment was administered according to tumor location, histologic grade, and extent of resection. The impacts of histologic grade, focal copy number gain on chromosome 1q, and DNA methylation profiles were studied for those undergoing surgery and immediate postoperative conformal radiation therapy (CRT). METHODS: ACNS0121 included 356 newly diagnosed patients (ages 1 to 21 years). Patients with classic supratentorial ependymoma were observed after gross total resection (GTR). Those undergoing subtotal resection received chemotherapy, second surgery, and CRT. The remaining patients received immediate postoperative CRT after near-total resection or GTR. CRT was administered with a 1.0-cm clinical target volume margin. The cumulative total dose was 59.4 Gy, except for patients who underwent GTR and were younger than age 18 months (who received 54 Gy). Patients were enrolled between October 2003 and September 2007 and were observed for 5 years. Supratentorial tumors were evaluated for RELA fusion; infratentorial tumors, for chromosome 1q gain. Classification of posterior fossa groups A and B was made by methylation profiles. RESULTS: The 5-year EFS rates were 61.4% (95% CI, 34.5% to 89.6%), 37.2% (95% CI, 24.8% to 49.6%), and 68.5% (95% CI, 62.8% to 74.2%) for observation, subtotal resection, and near-total resection/GTR groups given immediate postoperative CRT, respectively. The 5-year EFS rates differed significantly by tumor grade ( P = .0044) but not by age, location, RELA fusion status, or posterior fossa A/posterior fossa B grouping. EFS was higher for patients with infratentorial tumors without 1q gain than with 1q gain (82.8% [95% CI, 74.4% to 91.2%] v 47.4% [95% CI, 26.0% to 68.8%]; P = .0013). CONCLUSION: The EFS for patients with ependymoma younger than 3 years of age who received immediate postoperative CRT and for older patients is similar. Irradiation should remain the mainstay of care for most subtypes.

21 July 2017 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
PPPooja Panwalkar
Pooja Panwalkar
JCJonathan Clark
Jonathan Clark
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy
DHDebra Hawes
Debra Hawes
FYFusheng Yang
Fusheng Yang
SVSriram Venneti
Sriram Venneti